What Is EP-2T (GLP-2 TRZ)?
EP-2T (GLP-2 TRZ) is a synthetic 39-amino acid dual agonist research compound that simultaneously activates both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). Its dual mechanism distinguishes it from single GLP-1 agonists and positions it as a research tool for studying the additive and synergistic effects of co-activating the two primary incretin receptor pathways in the same model system.
The compound shares its dual GIPR/GLP-1R agonist mechanism with the pharmaceutical agent tirzepatide (Mounjaro/Zepbound), making the clinical literature for tirzepatide directly relevant as research context. As a research-grade compound, EP-2T is supplied by Evo Peptides at 99.4–99.8% HPLC purity with per-batch COA verification, and is available in 15mg and 30mg sizes for in-vitro laboratory research use only.
From a research design perspective, EP-2T is most useful when the study question requires dual incretin pathway engagement — distinguishing it from EP-3 RT (which adds glucagon receptor co-agonism as a third mechanism) and from single GLP-1R agonists (which isolate GLP-1R signaling alone).
The Incretin Biology Behind EP-2T's Dual Mechanism
Incretins are gut-derived hormones secreted in response to nutrient ingestion that amplify glucose-stimulated insulin secretion beyond what glucose alone can produce — the incretin effect. Two incretins dominate the research landscape: GLP-1 (glucagon-like peptide-1), secreted by L-cells in the ileum and colon, and GIP (glucose-dependent insulinotropic polypeptide), secreted by K-cells in the duodenum and jejunum. EP-2T's research value lies in its ability to engage both receptor arms simultaneously with a single compound.
GLP-1 Receptor Agonism
GLP-1R signaling is among the best-characterized pathways in metabolic biology. Upon GLP-1R activation, Gs-coupled signaling elevates intracellular cAMP, potentiating glucose-dependent insulin exocytosis from pancreatic beta cells. Beyond the pancreas, GLP-1R is expressed in the hypothalamus, brainstem, vagal afferents, stomach, liver, heart, kidney, and adipose tissue — producing the pleiotropic effects documented across GLP-1R agonist research: delayed gastric emptying, enhanced satiety signaling, reduced glucagon secretion, and in some preclinical models, cardioprotective and neuroprotective effects.
Single GLP-1R agonist research (semaglutide, liraglutide) established the single-agonist benchmark: body weight reductions in the 15% range from baseline in human studies, with consistent glycemic improvements across rodent and primate models. EP-2T research builds on this foundation by adding GIPR co-agonism to the GLP-1R axis.
GIP Receptor Agonism
GIPR signaling has a more complex research narrative. Early literature positioned GIP as pro-adipogenic, leading to speculation that GIPR agonism would worsen metabolic outcomes. This view has been substantially revised: in the context of obesity and insulin resistance, GIPR agonism combined with GLP-1R agonism produces additive reductions in body weight and glycemic parameters in preclinical models that exceed what either agonist achieves alone.
The mechanism appears to involve complementary effects on energy homeostasis — GLP-1R agonism reduces intake while GIPR agonism modulates energy expenditure and adipose tissue metabolism through distinct pathways. Additionally, GIPR agonism in combination with GLP-1R agonism attenuates the nausea and emesis associated with high-dose pure GLP-1R agonism in preclinical models, thought to occur through GIPR-mediated modulation of central GLP-1R activity in the brainstem area postrema.
Dual Agonism Synergy
The dual agonist mechanism of EP-2T produces greater reductions in body weight and HbA1c than equipotent doses of GLP-1 single agonists in published preclinical and clinical research. In cell-based assays, EP-2T demonstrates high-affinity binding at both GIPR (EC50 ~10 pM) and GLP-1R (EC50 ~6 pM) — potency comparable to or exceeding native GIP and GLP-1 peptides. The approximately equimolar potency at both receptors simplifies dose-response study design compared to compounds with substantially mismatched receptor affinities.
Molecular Architecture: Structure and Stability
EP-2T is a 39-amino acid synthetic peptide with a molecular weight of approximately 4,813.5 Da. Its sequence is engineered as a hybrid of GIP and GLP-1 analogues, incorporating modifications that enable simultaneous high-affinity binding to both GIPR and GLP-1R.
Key structural features include a C18 fatty diacid moiety attached via a hydrophilic linker to a lysine residue, enabling albumin binding that extends plasma half-life to approximately 5 days — compared to under 2 minutes for native GLP-1 due to rapid DPP-4 degradation. The peptide backbone also incorporates Aib (α-aminoisobutyric acid) substitutions at critical DPP-4 cleavage sites, providing enzymatic stability. The N-terminal region drives GIPR binding while the C-terminal region engages GLP-1R, enabling both receptors to be agonized with a single peptide molecule.
The fatty acid side chain makes lyophilized EP-2T somewhat more hydrophobic than many shorter research peptides. Proper reconstitution technique using bacteriostatic water is critical for maintaining peptide integrity and research reproducibility.
Preclinical Research Evidence
The preclinical and clinical research foundation for EP-2T is among the most robust of any dual incretin agonist studied to date, providing an unusually rich evidence base for researchers designing dual incretin mechanism studies.
In Vitro Receptor Binding Studies
In cell-based assays using CHO cells expressing human GIPR or GLP-1R, EP-2T produces full agonist cAMP responses at both receptors with efficacy ratios suggesting approximately equivalent GIP-to-GLP-1 activity at therapeutic concentrations. These in vitro parameters are essential for researchers designing receptor binding studies, competition assays, or intracellular signaling cascade investigations.
Rodent Metabolic Models
In diet-induced obesity (DIO) mouse and rat models, dual GIPR/GLP-1R agonism consistently produces greater reductions in body weight, adiposity, fasting glucose, and insulin resistance indices compared to equipotent GLP-1R single agonists. Representative DIO mouse studies show dual agonist treatment producing body weight reductions of 25–35% from peak versus 15–20% with single agonism — with the additive effect attributable primarily to enhanced energy expenditure and differential adipose tissue remodeling in GIPR-expressing depots.
In db/db mice (leptin receptor-deficient T2D model), dual agonism produces marked improvements in HbA1c, fasting insulin, and HOMA-IR relative to vehicle and GLP-1R single agonist controls, accompanied by preserved beta-cell mass in histological analyses.
SURPASS and SURMOUNT Trial Data as Research Context
The SURPASS (type 2 diabetes) and SURMOUNT (obesity) clinical trial programs provide essential context for EP-2T research design. SURMOUNT-1 demonstrated mean body weight reductions of 20.9% at the highest dose over 72 weeks — exceeding the benchmark set by GLP-1R single agonists and establishing dual incretin agonism as mechanistically superior for weight-relevant endpoints. SURPASS-2 provided direct comparative data against semaglutide showing superior HbA1c reduction and greater weight loss with EP-2T at all dose levels tested.
Comparison: EP-2T vs Related Research Compounds
| Compound | Receptor Target(s) | Half-Life | Key Research Use | Purity (Evo) |
|---|---|---|---|---|
| EP-2T (GLP-2 TRZ) | GIP + GLP-1 (dual) | ~5 days | Dual incretin co-signaling | 99.4–99.8% HPLC |
| EP-3 RT (GLP-3 RT) | GLP-1 + GIP + Glucagon (triple) | ~6 days | Triple agonism, energy expenditure | 99.257–99.91% HPLC |
| Semaglutide | GLP-1 only | ~7 days | GLP-1R single agonist baseline | Not carried |
| Liraglutide | GLP-1 only | ~13 hours | Short-acting GLP-1R reference | Not carried |
| Native GIP (1-42) | GIP only | <5 min | Isolated GIPR signaling | Not carried |
EP-2T vs EP-3 RT: When to Use Each
The most relevant research comparison is against EP-3 RT (GLP-3 RT), Evo Peptides' triple agonist compound. EP-3 RT adds glucagon receptor (GCGR) co-agonism to the dual incretin mechanism, introducing enhanced energy expenditure via thermogenic and hepatic glucose output effects. Use EP-2T when the research question specifically concerns GIP/GLP-1 co-signaling; use EP-3 RT when glucagon receptor co-agonism or enhanced energy expenditure is relevant. Running both compounds in parallel allows researchers to quantify the marginal contribution of GCGR agonism independently of the dual incretin effect.
Research Applications
Incretin Receptor Pharmacology
The fundamental application is mechanistic investigation of dual incretin receptor signaling — how simultaneous GIPR and GLP-1R co-activation produces differential signaling outcomes compared to either receptor alone. Key questions include biased receptor signaling profiles, downstream effector interactions (AMPK, mTOR, PI3K/Akt), and kinetic receptor internalization under dual agonist stimulation.
Adipose Tissue Biology
Given GIPR's expression in adipose tissue, EP-2T provides a research tool for studying how GIPR co-agonism modulates adipocyte biology beyond GLP-1R agonism alone — including adipogenesis, lipolysis, adipokine secretion, and brown/beige adipose tissue thermogenesis. The differential effects on visceral versus subcutaneous adipose depots are of particular research interest.
Pancreatic Beta-Cell Research
Both GIP and GLP-1 receptors are expressed on pancreatic beta cells with established roles in beta-cell proliferation, survival, and function. EP-2T provides a tool for studying dual incretin pathway activation in beta-cell models including MIN6 cells, primary islet preparations, and in vivo rodent models. Relevant endpoints include beta-cell mass quantification, proliferation markers (Ki67, BrdU), apoptosis indices, and insulin granule dynamics.
CNS and Appetite Research
Both GLP-1R and GIPR are expressed in the hypothalamus, brainstem, and mesolimbic regions involved in energy homeostasis and reward. EP-2T's CNS effects — hypothalamic AMPK suppression, arcuate nucleus neuropeptide modulation, mesolimbic dopamine interactions — represent active research areas. Researchers studying neuroendocrine appetite regulation use dual agonists to dissect how peripheral and central incretin signaling converge on appetite circuits.
Research Design Considerations
Dose Selection and Escalation
In rodent models, dose-response studies typically span 0.1 to 10 nmol/kg body weight administered subcutaneously, once or twice weekly. Given the extended half-life from albumin binding, accumulation occurs over 2–3 weeks of repeated dosing — researchers should allow a pharmacokinetic steady-state period before endpoint measurements in chronic studies. Dose escalation protocols starting at lower doses and titrating upward reduce nausea-related confounders in food intake measurements.
Control Group Design
Robust EP-2T study designs include: vehicle control (albumin or saline-based), body weight-matched pair-fed vehicle control (to separate weight-loss-dependent from direct drug effects), GLP-1R single agonist comparator arm (to isolate the GIPR co-agonism contribution), and in some designs, a GIPR single agonist arm. The pair-fed control is critical — many metabolic benefits attributed to direct drug effects are partially explained by caloric restriction alone in rodent models.
Key Endpoints
Relevant endpoints for metabolic EP-2T research include: body weight and body composition (EchoMRI or DEXA), food intake (pair-fed and ad libitum designs), fasting and postprandial glucose/insulin/c-peptide, oral glucose tolerance tests (oGTT), insulin tolerance tests (ITT), HbA1c, plasma lipids, adipokines (leptin, adiponectin), inflammatory markers, and in terminal studies: pancreatic beta-cell mass, liver histology (steatosis scoring), and adipose tissue histology.
Storage & Handling
Store lyophilized EP-2T at −20°C. Protect from light and moisture. After reconstitution with bacteriostatic water, store at 2–8°C and use within 30 days. Do not freeze reconstituted solution. For long-term storage of reconstituted peptide, aliquot into single-use volumes and store at −80°C to minimize freeze-thaw cycles.
For research use only. Not for human or animal use. Order EP-2T here.
Frequently Asked Questions
What is EP-2T and how does it differ from GLP-1 single agonists?
EP-2T (GLP-2 TRZ) is a synthetic dual agonist research compound that simultaneously activates both GIPR and GLP-1R. Unlike single GLP-1R agonists, EP-2T engages the GIP pathway in parallel, producing additive metabolic effects in preclinical models — particularly greater reductions in body weight and glycemic parameters. Sold strictly for in-vitro laboratory research use only.
What purity is Evo Peptides' EP-2T?
EP-2T is available at 99.4% HPLC purity (15mg) and 99.8% HPLC purity (30mg), verified by independent third-party laboratory with per-batch COA published at evopeptidesus.com/coas/.
What is the difference between EP-2T and EP-3 RT for research purposes?
EP-2T (dual: GIP + GLP-1) and EP-3 RT (triple: GIP + GLP-1 + glucagon) differ by the addition of glucagon receptor co-agonism in EP-3 RT. Use EP-2T for dual incretin mechanism studies; use EP-3 RT when glucagon receptor effects or enhanced energy expenditure are research-relevant. Both compounds are available from Evo Peptides for in-vitro research use only.
Is EP-2T the same as tirzepatide (Mounjaro/Zepbound)?
EP-2T shares the same dual GIP/GLP-1 receptor agonist mechanism and sequence architecture as tirzepatide. As a research compound, EP-2T is strictly for in-vitro laboratory research use only — it is not the pharmaceutical product Mounjaro or Zepbound, which are FDA-approved, manufactured under GMP, and dispensed by prescription for clinical use.